Voyager Therapeutics, Inc.

📍 Cambridge, United States🗓 Founded 2014👥 202 employees💰 Last funded 2021
Biotechnology Research🌐 voyagertherapeutics.com
Website LinkedIn
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com. Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2014
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Voyager Therapeutics, Inc.?
Voyager Therapeutics, Inc. has 1 investors on record on gritt.io and 1 late-stage investors.
When did Voyager Therapeutics, Inc. last raise funding?
The most recent investment in Voyager Therapeutics, Inc. recorded on gritt.io was in 2021.
When was Voyager Therapeutics, Inc. founded?
Voyager Therapeutics, Inc. was founded in 2014.
What industry is Voyager Therapeutics, Inc. in?
Voyager Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Voyager Therapeutics, Inc. based?
Voyager Therapeutics, Inc. is headquartered in Cambridge, United States.